An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers - 09/10/21
, Junhua Zhang e, ⁎, 2 Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To gain a deeper understanding of the hot topics and future prospects of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors treatment of cancer through scientometric analysis of the top-100 most cited clinical trials.
Materials and methods |
We searched the Web of Science Core Collection database from 1980 to June 2019. Two reviewers independently screened the top-100 most cited clinical trials that defined by the National Institutes of Health starting from the most cited article. Title, year of publication, citations, type of cancer, and focused aspects of outcomes were extracted from included clinical trials. VOSviewer software (version 1.6.9) and Excel 2016 were used to do statistical analysis. The evidence mapping was used to present the relationship between cancers, drugs, citations, and outcomes, etc.
Results |
The top-100 most cited clinical trials published from 2010 to 2018 in nine journals with high impact factor (IF) (IF2018:6.68–70.67), and Lancet Oncology (USA) published the most clinical trials (n = 29, IF2018 = 35.3856). The total number of citations of the top-100 most cited clinical trials was from 59 to 5606. 920 authors from 34 countries and 458 organizations participated in publishing the top-100 most cited clinical trials. The USA (n = 95) and Memorial Sloan-Kettering Cancer Center (n = 31) contributed the most publications. Based on the evidence mapping, there are 25 different types of cancers (e.g. lung cancer, melanoma, and renal cell cancer) and five focused aspects of outcomes (e.g. safety and efficacy).
Conclusion |
The USA was the dominant country. Anti-PD-1/PD-L1 drugs were widely used to treat lung cancer, melanoma, renal cell cancer, and Hodgkin lymphoma. More exploration should be done to explore the use of anti-PD-1/PD-L1 drugs to treat more type of cancers in future research.
Le texte complet de cet article est disponible en PDF.Highlights |
• | This is the first study that analysis the top-100 most cited clinical trials of PD-1 and PD-L1 drugs to treat cancer. |
• | The USA and Memorial Sloan-Kettering Cancer Center contributed the most publications. |
• | Anti-PD-1/PD-L1 drugs were widely used to treat lung cancer, melanoma, renal cell cancer, and Hodgkin lymphoma. |
• | More exploration should be done to explore the use of anti-PD-1/PD-L1 drugs to treat more type of cancers in future research. |
Keywords : scientometric analysis, evidence mapping, PD-1/PD-L1, cancer, clinical trials, citations
Plan
Vol 143
Article 112238- novembre 2021 Retour au numéro
Article précédent
- The combination of nanoscaffolds and stem cell transplantation: Paving a promising road for spinal cord injury regeneration
- Xiaokun Chen, Yiyang Wang, Gang Zhou, Xianghui Hu, Shiyuan Han, Jun Gao
- Ex vivo expansion and functional activity preservation of adult hematopoietic stem cells by a diarylheptanoid from Curcuma comosa
- Nopmullee Tanhuad, Umnuaychoke Thongsa-ad, Nareerat Sutjarit, Ploychompoo Yoosabai, Wittaya Panvongsa, Sirapope Wongniam, Apichart Suksamrarn, Pawinee Piyachaturawat, Usanarat Anurathapan, Suparerk Borwornpinyo, Arthit Chairoungdua, Suradej Hongeng, Kanit Bhukhai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?